Chronic Lymphoblastic Leukemia

Arzerra, Fludara, and Cytoxan Promising for Previously Untreated CLL (02-1-2010)

The combination of Arzerra™ (ofatumumab), Fludara® (fludarabine), and Cytoxan® (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL). These results were presented at the 2009 annual meeting... Continue Reading

Treanda® and Rituxan® Effective Initial Therapy for CLL (01-6-2010)

According to the results of a Phase II clinical trial, the combination of Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for the initial treatment of patients with advanced chronic lymphocytic leukemia (CLL). These results were... Continue Reading

Treanda® and Rituxan® Effective Initial Therapy for CLL (01-6-2010)

According to the results of a Phase II clinical trial, the combination of Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for the initial treatment of patients with advanced chronic lymphocytic leukemia (CLL). These results were... Continue Reading

Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (10-28-2009)

The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). Chronic... Continue Reading

Arzerra™ Effective For CLL (03-8-2009)

Arzerra™ Effective For CLL Arzerra™ (ofatumumab), a human anti-CD20 monoclonal antibody, is effective for the treatment of patients with refractory chronic lymphocytic leukemia (CLL), according to the results of a study presented at the annual meeting... Continue Reading

Rituxan® Delays Progression of Chronic Lymphocytic Leukemia (03-8-2009)

Rituxan® Delays Progression of Chronic Lymphocytic Leukemia According to the results of two Phase III clinical trials, the addition of Rituxan® (rituximab) to chemotherapy improves progression-free survival among patients with chronic lymphocytic leukemia... Continue Reading

FCR-Lite Is Safe and Effective in Previously Untreated CLL (03-8-2009)

FCR-Lite Is Safe and Effective in Previously Untreated CLL FCR-Lite, a drug regimen that consists of Fludara® (fludarabine), Cytoxan® (cyclophosphamide), and Rituxan® (rituximab), is highly effective in previously untreated patients with chronic lymphocytic... Continue Reading

Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL (03-8-2009)

Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL Patients with chronic lymphocytic leukemia (CLL) treated with Fludara® (fludarabine), followed by consolidation with Cytoxan® (cyclophosphamide), and... Continue Reading

Revlimid® Shows Promise as First-line Therapy of CLL (03-8-2009)

Revlimid® Shows Promise as First-line Therapy of CLL According to the results of two studies presented at the 2008 annual meeting of the American Society of Hematology (ASH), Revlimid® (lenalidomide) appears to be effective for the initial treatment... Continue Reading

Genasense® Improves Outcomes in Chronic Lymphocytic Leukemia (03-8-2009)

Genasense® Improves Outcomes in Chronic Lymphocytic Leukemia The addition of Genasense® (oblimersen, Bcl-2 antisense) to chemotherapy appears to improve outcomes among patients with chronic lymphocytic leukemia (CLL) compared with chemotherapy only.... Continue Reading

« Previous PageNext Page »